ClinicalTrials.gg
CompletedNCT05681715Updated Nov 6, 2025Results posted

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

A Phase 3 interventional study of Rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 27 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.

Enrollment
6th of 10
62 · median 67
Started
2023
the only one that year
Phase 3
7 of 10
2 open now
Registered
5th of 10
by date
Lead sponsor
9 of 10
UCB Biopharma SRL

Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 6th largest by enrollment, is the only one that started in 2023, is one of 7 in phase 3, and was the 5th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rozanolixizumab

rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rozanolixizumab in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • generalized Myasthenia Gravis
  • gMG
  • rozanolixizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG)
  • Study participant is willing to perform and capable of performing home self-administration
  • Study participant is considered by the investigator for additional rozanolixizumab treatment with the posology proposed in this study.
  • Body weight ≥35 kg
  • Study participants may be male or female

Exclusion criteria

Exclusion Criteria:

  • Study participant has a known to other anti-Fc receptor (FcRn) medications, to any components of the study medication, to any of the (including polysorbate 80), or has a known history of hyperprolinemia, since both polysorbate 80 and L-proline are constituents of the rozanolixizumab formulation
  • Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current or history of nontuberculous mycobacterial infection (NTMBI)
  • Study participant has a active infection or a history of serious infection (resulting in hospitalization or requiring IV antibiotic treatment) within 6 weeks before the Baseline Visit
  • The study participant previously participated in any rozanolixizumab MG study and met any mandatory withdrawal criteria (unless the reason is directly related to MG0020 participation) or mandatory study drug discontinuation criteria.
  • Study participant has received a within 4 weeks before starting treatment, or a Bacillus Calmette-Guérin (BCG) vaccine within 1 year before starting treatment; or intends to have a live vaccination during the course of the study or within 8 weeks following the last dose of rozanolixizumab
  • Study participant with severe (defined as Grade 3 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab Sequence 1: Syringe Driver - Manual Push

    Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.

    Drug: Rozanolixizumab

  • Experimental
    Rozanolixizumab Sequence 2: Manual Push - Syringe Driver

    Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.

    Drug: Rozanolixizumab

Interventions

  • Rozanolixizumab self-administration via Syringe Driver or Manual Push.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12)

    Successful self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.

    Time frame: Week 12 (last dose of Self-administration Period 1)

  2. Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18)

    Successful Self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.

    Time frame: Week 18 (last dose of Self-administration Period 2)

Secondary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26])

    An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE starting on or after the date of first administration of rozanolixizumab in the study, up to and including 8 weeks (56 days) after the final dose.

    Time frame: From Week 1 up to the End of Study Visit (Week 26)

  2. Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods

    The local site reactions up to 24 hours after each administration were defined as AEs reported as local site reactions as per case report form within one day after RLZ administration.

    Time frame: Up to 24 hours after each administration during the Training Period (Baseline to Week 6) and Self-administration Periods (Week 7 to Week 18)

  3. Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study

    Medication errors were defined as an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the study participant. Medication Errors associated with adverse reactions during the 2 Self-administration Periods were measured.

    Time frame: During the Self-administration Periods (Week 7 to Week 18)

07

Results

Posted May 7, 2025

Participant flow

The study started to enroll participants in April 2023 and concluded in April 2024.

Training Period (6-weeks)
Participant flow — Training Period (6-weeks)
MilestoneAll Participants: Training PeriodSequence 1: RLZ Syringe Driver (SRD) - RLZ Manual Push (MP)Sequence 2: RLZ MP - RLZ SRD
Started6200
Completed5500
Not completed700
Withdrew: Adverse event300
Withdrew: Consent withdrawn by participant (not due to ae)100
Withdrew: Not eligible for sa but continued in study300
Self-administration Period 1 (6 Weeks)
Participant flow — Self-administration Period 1 (6 Weeks)
MilestoneAll Participants: Training PeriodSequence 1: RLZ Syringe Driver (SRD) - RLZ Manual Push (MP)Sequence 2: RLZ MP - RLZ SRD
Started02827
Completed02326
Not completed051
Withdrew: Diagnosis change to amyotrophic lateral sclerosis010
Withdrew: Consent withdrawn by participant (not due to ae)001
Withdrew: Adverse event010
Withdrew: Participant became ineligible for sa010
Withdrew: Missed infusion at visit 13, sa period1 incomplete020
Self-administration Period 2 (6 Weeks)
Participant flow — Self-administration Period 2 (6 Weeks)
MilestoneAll Participants: Training PeriodSequence 1: RLZ Syringe Driver (SRD) - RLZ Manual Push (MP)Sequence 2: RLZ MP - RLZ SRD
Started02526
Completed02526
Not completed000

Outcome measures

PrimaryPercentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12)

Successful self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.

Time frame:
Week 12 (last dose of Self-administration Period 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12)
percentage of participantsPeriod 1: RLZ SRDPeriod 1: RLZ MP
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 13 (Week 12)100100
PrimaryPercentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18)

Successful Self-administration was defined by the participant (i) choosing the correct infusion site, (ii) administering SC, and (iii) delivering the intended dose.

Time frame:
Week 18 (last dose of Self-administration Period 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18)
percentage of participantsPeriod 2: RLZ SRDPeriod 2: RLZ MP
Percentage of Participants With Successful Self-administration of Rozanolixizumab (With Correct Use of Syringe Driver and Manual Push, Respectively) During the Self-administration Period at Visit 19 (Week 18)100100
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26])

An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE starting on or after the date of first administration of rozanolixizumab in the study, up to and including 8 weeks (56 days) after the final dose.

Time frame:
From Week 1 up to the End of Study Visit (Week 26)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26])
percentage of participantsPeriod 1: RLZ SRDPeriod 1: RLZ MPPeriod 2: RLZ SRDPeriod 2: RLZ MPRLZ Total
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) After Syringe Driver or Manual Push Self-administration From Visit 2 (Week 1) up to the End of Study Visit (Visit 21 [Week 26])35.729.626.938.575.8
SecondaryPercentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods

The local site reactions up to 24 hours after each administration were defined as AEs reported as local site reactions as per case report form within one day after RLZ administration.

Time frame:
Up to 24 hours after each administration during the Training Period (Baseline to Week 6) and Self-administration Periods (Week 7 to Week 18)
Reported as:
Number · percentage of participants
Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods
percentage of participantsAll Participants: Training PeriodPeriod 1: RLZ SRDPeriod 1: RLZ MPPeriod 2: RLZ SRDPeriod 2: RLZ MP
Percentage of Participants With Local Site Reactions up to 24 Hours After Each Administration During the Training Period and Self-administration Periods00000
SecondaryPercentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study

Medication errors were defined as an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the study participant. Medication Errors associated with adverse reactions during the 2 Self-administration Periods were measured.

Time frame:
During the Self-administration Periods (Week 7 to Week 18)
Reported as:
Number · percentage of participants
Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study
percentage of participantsPeriod 1: RLZ SRDPeriod 1: RLZ MPPeriod 2: RLZ SRDPeriod 2: RLZ MP
Percentage of Participants With Medication Errors Associated With Adverse Reactions During the 2 Self-administration Periods of the Study0000

Adverse events

Collected over From Week 1 up to the End of Study Visit (Week 26). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants: Training Period0/62 (0%)1/62 (1.6%)19/62 (30.6%)
Self-Administration Period 1 and 2: RLZ SRD0/54 (0%)3/54 (5.6%)6/54 (11.1%)
Self-Administration Period 1 and 2: RLZ MP0/53 (0%)1/53 (1.9%)6/53 (11.3%)
RLZ Total0/62 (0%)7/62 (11.3%)24/62 (38.7%)
Most frequent serious events
Most frequent serious events
EventAll Participants: Training PeriodSelf-Administration Period 1 and 2: RLZ SRDSelf-Administration Period 1 and 2: RLZ MPRLZ Total
Myasthenia gravisNervous system disorders1/620/540/532/62
Myocardial infarctionCardiac disorders0/620/541/531/62
Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/621/540/531/62
Transient ischaemic attackNervous system disorders0/621/540/531/62
DyspnoeaRespiratory, thoracic and mediastinal disorders0/621/540/531/62
Urinary tract infectionInfections and infestations0/620/540/531/62
Most frequent other events
Most frequent other events
EventAll Participants: Training PeriodSelf-Administration Period 1 and 2: RLZ SRDSelf-Administration Period 1 and 2: RLZ MPRLZ Total
HeadacheNervous system disorders12/624/541/5313/62
COVID-19Infections and infestations4/620/541/537/62
PyrexiaGeneral disorders4/621/543/536/62
DiarrhoeaGastrointestinal disorders4/620/541/535/62
NasopharyngitisInfections and infestations0/623/542/535/62

Baseline characteristics

Baseline characteristics refers to the Safety set which included all study participants who received at least 1 dose of investigational medicinal product (IMP) (partial or full).

Age, Continuous
Age, Continuous(years)All Participants: Training Period
Mean53.3 ± 15.7
Age, Customized
Age, Customized(Participants)All Participants: Training Period
18 - <65 years45
65 - <85 years17
>=85 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Participants: Training Period
Female35
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants: Training Period
Asian5
Black or African American1
White55
Other/Mixed1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants: Training Period
Hispanic or Latino5
Not Hispanic or Latino57
08

Study locations

27 sites
  • Mg0020 50092
    Orange, California 92868, United States
  • Mg0020 50099
    San Francisco, California 94143, United States
  • Mg0020 50561
    Lexington, Kentucky 40536-0284, United States
  • Mg0020 50090
    Winston-Salem, North Carolina 27157, United States
  • Mg0020 50560
    Edmonton, Canada
  • Mg0020 50069
    Toronto, Canada
  • Mg0020 20161
    Tbilisi, Georgia
  • Mg0020 20165
    Tbilisi, Georgia
  • Mg0020 20305
    Tbilisi, Georgia
  • Mg0020 40140
    Göttingen, Germany
  • Mg0020 40177
    Münster, Germany
  • Mg0020 40144
    Milan, Italy
  • Mg0020 40146
    Pavia, Italy
  • Mg0020 40150
    Roma, Italy
  • Mg0020 20068
    Chiba, Japan
  • Mg0020 20078
    Hanamaki-shi, Japan
  • Mg0020 20077
    Sendai, Japan
  • Mg0020 20076
    Shinjuku-ku, Japan
  • Mg0020 40155
    Gdansk, Poland
  • Mg0020 40727
    Lodz, Poland
  • Mg0020 40153
    Poznan, Poland
  • Mg0020 40729
    Niš, Serbia
  • Mg0020 40160
    Barcelona, Spain
  • Mg0020 40267
    Barcelona, Spain
  • Mg0020 40308
    San Sebastián de los Reyes, Spain
  • Mg0020 40168
    Nottingham, United Kingdom
  • Mg0020 40163
    Oxford, United Kingdom
09

References and documents

Publications

  • Bril V, Antozzi C, Berkowicz T, Druzdz A, Gandhi Mehta RK, Mahuwala ZK, Zschuntzsch J, Boehnlein M, Kerbusch V, Lavrov A, Morris M, Singh P, Leite MI. Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study. J Neurol. 2025 Oct 11;272(10):686. doi: 10.1007/s00415-025-13420-6. PubMed 41074934 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Apr 2024, 12 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 12, 2023
StartActual
Apr 17, 2023
Primary completionActual
Apr 23, 2024
CompletionActual
Apr 23, 2024
Results first posted
May 7, 2025
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05681715
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Apr 17, 2023
Primary completion
Apr 23, 2024
Completion
Apr 23, 2024
Results posted
May 7, 2025
Last update
Nov 6, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion